Welcome to our dedicated page for Endra Life Sciences SEC filings (Ticker: NDRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ENDRA Life Sciences Inc. (NDRA) SEC filings page provides direct access to the company’s regulatory disclosures, including Forms 10‑K, 10‑Q, 8‑K, registration statements and proxy materials. These documents explain how ENDRA is developing its Thermo Acoustic Enhanced UltraSound (TAEUS®) platform for liver fat measurement and other thermoacoustic applications, and how it manages capital and risk as a Nasdaq‑listed issuer in the electromedical and electrotherapeutic apparatus manufacturing industry.
Through annual and quarterly reports, investors can review detailed discussions of ENDRA’s business strategy, risk factors, research and development priorities, and its focus on steatotic liver disease (SLD), metabolic dysfunction‑associated steatohepatitis (MASH) and GLP‑1 therapy management. Current reports on Form 8‑K describe material events such as private placements with warrants, at‑the‑market (ATM) equity agreements, the launch of a digital asset treasury (DAT) strategy, and the engagement of Arca Investment Management and Anchorage Digital Bank to manage and custody cryptocurrency holdings.
Filings also document corporate governance and capital structure decisions, including amendments to the certificate of incorporation to increase authorized common shares, updates to the 2016 Omnibus Incentive Plan, and Nasdaq listing compliance matters related to stockholders’ equity. Registration statements on Form S‑1/A outline proposed offerings, use of proceeds for TAEUS development and DAT activities, and extensive risk factor sections addressing both medical device and digital asset considerations.
On Stock Titan, these filings are paired with AI‑powered summaries that highlight key points from lengthy documents, helping users quickly understand complex topics such as De Novo regulatory plans for TAEUS Liver, equity financing terms, warrant structures and DAT‑related risk disclosures. Investors can also monitor insider‑related information through ownership tables and compensation discussions included in proxy statements and periodic reports.
ENDRA Life Sciences Inc. files its annual report describing a medical imaging business focused on its Thermo-Acoustic Enhanced Ultrasound (TAEUS) platform for liver fat assessment in metabolic disease. The company is early-stage, with an accumulated deficit of $110.4 million as of December 31, 2025 and an auditor warning of substantial doubt about its ability to continue as a going concern.
Management has halted clinical activities needed for a new FDA De Novo submission for its liver application after cost reductions, cut headcount from 11 to 4 employees, and significantly scaled back commercial operations to conserve cash. In March 2026, the board began evaluating strategic alternatives, including investments, mergers, asset sales or a potential sale or merger of the company, with no outcome guaranteed.
ENDRA also introduces a Digital Asset Treasury strategy, run with Arca Investment Management, to invest excess capital primarily in one to five decentralized finance cryptocurrencies, initially HYPE, held with Anchorage Digital Bank. This financial initiative operates alongside its core TAEUS commercialization plans targeting pharmaceutical trials and metabolic care markets.
ENDRA Life Sciences reported a smaller net loss for 2025 while continuing to invest in its TAEUS thermoacoustic liver imaging platform and reviewing strategic alternatives. The company focuses on steatotic liver disease, aiming to offer a more accessible, ultrasound-based diagnostic option.
Operating expenses for 2025 fell to $5.8 million from $10.8 million in 2024, reflecting streamlining efforts, including a prior non-cash inventory charge. Net loss improved to $7.0 million from $11.5 million, helped by lower research, sales and marketing, and general and administrative costs.
In the fourth quarter of 2025, cash used in operations was $1.6 million. As of December 31, 2025, ENDRA held $762,365 in cash and cash equivalents and $2.0 million in digital assets, forming part of its capital management strategy alongside lease and warrant liabilities.
ENDRA Life Sciences Inc. is launching a formal review of strategic alternatives aimed at maximizing shareholder value while continuing to pursue its TAEUS thermoacoustic imaging business. The Board will consider options such as strategic investments, mergers, business combinations, collaborations, asset sales, or a sale or merger of the Company, with Lucid Capital Management as financial advisor and K&L Gates as legal counsel. In connection with this shift, ENDRA reduced its workforce on March 19, 2026 and expects to record approximately $51,000 in pre-tax severance charges in the first quarter of 2026.
ENDRA Life Sciences reported that Chief Executive Officer Alexander Y. Tokman acquired 26,921 shares of common stock through a grant of restricted stock units (RSUs) at a price of $0.00 per share. These RSUs convert to common stock on a one-for-one basis and will vest in full on June 11, 2026. Following this award, Tokman directly holds 101,926 shares of common stock, and the holdings disclosure notes that this amount includes unvested RSUs.
ENDRA Life Sciences Inc. reported that its Chief Financial Officer, Richard Jacroux, received a grant of 13,461 shares of common stock as a stock award. The shares, structured as restricted stock units that convert one-for-one into common stock, will vest in full on June 11, 2026. Following this award, Jacroux holds 33,461 shares of common stock, including unvested restricted stock units.
ENDRA Life Sciences Inc. director Anthony DiGiandomenico reported a stock-based award of the company’s common stock. On January 21, 2026, he acquired 60,324 shares at a price of $0, representing restricted stock units (RSUs) that convert to common stock on a one-for-one basis. These RSUs will vest in full on January 21, 2027, meaning he will receive the underlying shares on that date if vesting conditions are met. After this grant, he beneficially owns 136,589 shares of ENDRA common stock, held directly, which includes unvested RSUs.
ENDRA Life Sciences director Michael Harsh reported an equity award of 60,324 shares on January 21, 2026. The filing shows these are restricted stock units (RSUs) that convert into common stock on a one-for-one basis and will vest in full on January 21, 2026. The transaction was recorded at a price of $0 per share, indicating a compensatory grant rather than an open-market purchase. Following this award, Harsh beneficially owned 65,710 shares of common stock, and his holdings include unvested RSUs.
ENDRA Life Sciences Inc. reported that its Chief Financial Officer, Richard Jacroux, acquired 20,000 shares of common stock on January 21, 2026. The shares come from restricted stock units that were granted at a price of $0 per share and convert into common stock on a one-for-one basis. After this transaction, he beneficially owns 20,000 common shares directly. The RSUs are scheduled to vest in full on January 21, 2027, meaning the CFO will receive all underlying shares on that date if vesting conditions are met.
ENDRA Life Sciences director Lou Basenese received a stock-based award from the company. On January 21, 2026, he was granted 60,324 shares of common stock in the form of restricted stock units (RSUs) at a grant price of $0 per share. Each RSU converts into one share of common stock.
The RSUs will vest in full on January 21, 2027, meaning they convert to common shares on that date if vesting conditions are met. After this grant, Basenese beneficially owned a total of 65,709 shares of ENDRA Life Sciences common stock, which the disclosure notes includes unvested RSUs, all held directly.
ENDRA Life Sciences Chief Executive Officer and Director Alexander Y. Tokman received 75,000 shares of common stock on January 21, 2026 as an equity award. These shares represent restricted stock units that convert into common stock on a one-for-one basis and will vest in full on January 21, 2027. Following this grant, Tokman beneficially owned 75,005 shares of ENDRA Life Sciences common stock directly.